{"filings":[{"id":2283161,"accession_number":"0001193125-26-353278","cik":1680581,"company_name":"Fulcrum Therapeutics, Inc.","ticker":"FULC","form_type":"8-K","filed_at":"2026-08-17T12:30:07+00:00","items":["1.01","3.02","5.01","5.02","7.01","9.01"],"status":"ready","headline":"Fulcrum to merge with Slate Medicines; Slate holders to own ~95% of combined company","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Merger values Slate at $350M, Fulcrum at $31.3M; post-close ownership: Slate holders ~55.9%, investors ~39.1%, Fulcrum ~5.0%.","$245M concurrent investment from existing Slate stockholders and new investors; combined cash runway into 2029.","Fulcrum to pay $270M cash dividend to pre-merger Fulcrum stockholders; company renamed Slate Medicines, Inc.","Fulcrum board set at 5 members, all designated by Slate; Fulcrum options with exercise price >$7.00 cancelled at close.","Termination fees: Fulcrum pays $10M, Slate pays $15M; Slate stockholders holding 78.65% support deal."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":1.0,"calibrated_materiality_score":1.0,"market_cap_usd":447775948.460177,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2144996,"accession_number":"0001193125-26-341385","cik":1680581,"company_name":"Fulcrum Therapeutics, Inc.","ticker":"FULC","form_type":"8-K","filed_at":"2026-08-10T12:43:36+00:00","items":["5.02"],"status":"ready","headline":"Fulcrum CFO Musso takes on principal accounting officer role as Tourangeau departs","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Greg Tourangeau, VP Finance and principal accounting officer, departs Fulcrum effective August 7, 2026.","CFO Alan Musso appointed principal accounting officer effective August 7, 2026, succeeding Tourangeau.","Musso receives no additional compensation for the added principal accounting officer duties.","No family relationships or material interests involving Musso were disclosed in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":447775948.460177,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1277676,"accession_number":"0001193125-26-282873","cik":1680581,"company_name":"Fulcrum Therapeutics, Inc.","ticker":"FULC","form_type":"8-K","filed_at":"2026-06-25T20:32:25+00:00","items":["5.07"],"status":"ready","headline":"Fulcrum stockholders elect three Class I directors, approve advisory compensation, ratify auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Sonja Banks, Alan Ezekowitz, Colin Hill elected as Class I directors for three-year terms ending 2029.","Advisory vote on named executive officer compensation approved with 50.7M for, 3.0M against.","Ratification of Ernst & Young as FY2026 auditor approved with 58.8M for, 36K against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":447775948.460177,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1000917,"accession_number":"0001193125-26-267659","cik":1680581,"company_name":"Fulcrum Therapeutics, Inc.","ticker":"FULC","form_type":"8-K","filed_at":"2026-06-11T20:30:16+00:00","items":["5.02"],"status":"ready","headline":"Fulcrum approves retention bonuses for CEO, CLO, CFO; accounting officer departs after restructuring","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO Alex Sapir receives $370,040 retention bonus; CLO Curtis Oltmans $195,480; CFO Alan Musso $195,200.","Bonuses payable on change in control or termination without cause after fulfilling transitional duties.","VP+ level employees added to change-in-control severance if terminated within 6 months before a CIC.","VP Finance & principal accounting officer Greg Tourangeau departs mutually; no disagreement on financial matters.","Restructuring follows discontinuation of pociredir for sickle cell disease, previously disclosed May 31, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":447775948.460177,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":860876,"accession_number":"0001193125-26-257376","cik":1680581,"company_name":"Fulcrum Therapeutics, Inc.","ticker":"FULC","form_type":"8-K","filed_at":"2026-06-04T20:05:17+00:00","items":["2.05","8.01"],"status":"ready","headline":"Fulcrum cuts workforce 85% after SCD drug failure; hires Leerink for strategic review","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Workforce reduced from 57 to 9 employees (~85% cut) after discontinuing pociredir for sickle cell disease.","Expects ~$4.2M in restructuring charges (severance, benefits) mostly in Q2 2026.","Engaged Leerink Partners as financial advisor to explore strategic alternatives including merger or sale.","No timeline set for strategic review; no assurance of any transaction."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":447775948.460177,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":777884,"accession_number":"0001193125-26-251394","cik":1680581,"company_name":"Fulcrum Therapeutics, Inc.","ticker":"FULC","form_type":"8-K","filed_at":"2026-06-01T20:05:16+00:00","items":["8.01","9.01"],"status":"ready","headline":"Fulcrum Therapeutics discontinues pociredir program in SCD; initiates strategic review","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Discontinued pociredir for sickle cell disease after FDA feedback; no viable regulatory path forward.","FDA cited secondary malignancy risk from another PRC2 inhibitor (Tazverik) withdrawn March 2026.","Company will explore strategic alternatives (merger, acquisition, etc.) and reduce operating expenses.","Held $333.3M in cash, cash equivalents, and marketable securities as of March 31, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":447775948.460177,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94653,"accession_number":"0001193125-26-178806","cik":1680581,"company_name":"Fulcrum Therapeutics, Inc.","ticker":"FULC","form_type":"8-K","filed_at":"2026-04-27T23:59:59+00:00","items":["1.02","2.02","5.02","9.01"],"status":"ready","headline":"Fulcrum Therapeutics Q1 net loss $18.9M, CFO retiring, CAMP4 license terminated, pociredir trial planned H2 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["CFO Alan Musso retiring; will stay until successor named then consultant through Feb 2027.","Terminated CAMP4 license for Diamond-Blackfan anemia program; no further milestone/royalty payments.","Q1 net loss $18.9M ($17.7M Q1 2025); cash $333.3M, runway into 2029.","Positive pociredir Phase 1b data: HbF induction, hemolysis/anemia improvements; registration-enabling trial H2 2026.","Board appointed Josh Lehrer M.D., independent, receives option for 64,000 shares at $8.08."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.25,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":447775948.460177,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107180,"accession_number":"0001193125-26-065190","cik":1680581,"company_name":"Fulcrum Therapeutics, Inc.","ticker":"FULC","form_type":"8-K","filed_at":"2026-02-24T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Fulcrum Therapeutics Q4/FY2025: positive pociredir Phase 1b HbF data; net loss widens to $74.9M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Positive 12-week pociredir Phase 1b results: mean absolute HbF increased 12.2% (7.1% to 19.3%); improvements in hemolysis, anemia, and VOC trends.","Fulcrum plans to initiate a potential registration-enabling trial in H2 2026 after FDA End-of-Phase meeting in Q2 2026.","Cash, cash equivalents, and marketable securities of $352.3M as of Dec 31, 2025; cash runway extended into 2029.","Net loss for FY2025 was $74.9M vs $9.7M in FY2024; R&D expenses decreased to $56.1M from $63.4M.","Discontinued bone marrow failure syndrome program; focus on pociredir and benign hematology pipeline."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.18,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":447775948.460177,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107179,"accession_number":"0001193125-26-009845","cik":1680581,"company_name":"Fulcrum Therapeutics, Inc.","ticker":"FULC","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Fulcrum reports ~$352.3M cash as of Dec 31, 2025; updates presentation for JPM conference","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary unaudited cash, cash equivalents and marketable securities of $352.3M as of December 31, 2025.","Updated corporate slide presentation (Exhibit 99.1) issued January 12, 2026, containing business and strategic updates.","Management to present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026 at 7:30 a.m. PT.","Presentation will be webcast live on Fulcrum's investor relations website."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":447775948.460177,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123515,"accession_number":"0001193125-25-314728","cik":1680581,"company_name":"Fulcrum Therapeutics, Inc.","ticker":"FULC","form_type":"8-K","filed_at":"2025-12-11T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Fulcrum Therapeutics prices $175M upsized public offering of common stock and pre-funded warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Priced underwritten offering of 11,851,853 shares at $13.50/share and pre-funded warrants for 1,111,193 shares at $13.499 each.","Gross proceeds of $175M; net proceeds estimated at $164.1M (or $188.1M if underwriter option exercised).","Offering upsized; underwriters granted 30-day option to purchase up to 1,944,456 additional shares.","Net proceeds to fund general corporate purposes, including R&D, clinical trials, and potential acquisitions.","Closing expected on or about December 11, 2025, subject to customary conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":447775948.460177,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123514,"accession_number":"0001193125-25-310509","cik":1680581,"company_name":"Fulcrum Therapeutics, Inc.","ticker":"FULC","form_type":"8-K","filed_at":"2025-12-08T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Fulcrum reports positive Phase 1b data for pociredir in SCD: 58% patients achieved HbF>=20% at 20 mg dose","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Mean absolute HbF increased 9.9% at Week 6 in 20 mg cohort (vs 5.6% in 12 mg); 7 of 12 patients (58%) achieved HbF ≥20%.","Clear dose-response: >3.75-fold mean HbF induction at Week 12 (n=6) vs 2.4-fold in 12 mg cohort.","Hemolysis markers improved at Week 6: indirect bilirubin -37%, LDH -37%, reticulocyte counts -33%.","Pociredir well-tolerated with no treatment-related SAEs or discontinuations; dosed in 148 adults to date.","Plans to submit IND for bone marrow failure syndromes (e.g., Diamond-Blackfan anemia) in Q2 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":447775948.460177,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123513,"accession_number":"0001193125-25-254619","cik":1680581,"company_name":"Fulcrum Therapeutics, Inc.","ticker":"FULC","form_type":"8-K","filed_at":"2025-10-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Fulcrum Therapeutics Q3 loss $19.6M; pociredir 20mg cohort enrolled, data due year-end","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, equivalents and marketable securities $200.6M; cash runway into 2028.","Net loss $19.6M in Q3 2025 versus $21.7M in Q3 2024; R&D spend $14.3M.","12 mg dose cohort of Phase 1b PIONEER trial showed dose-dependent HbF increase and VOC reduction.","Enrollment completed in 20 mg dose cohort (n=12); data expected by year-end 2025.","Plans to submit IND for bone marrow failure syndromes (DBA, 5q-, etc.) in Q4 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.87,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":447775948.460177,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140193,"accession_number":"0001193125-25-190746","cik":1680581,"company_name":"Fulcrum Therapeutics, Inc.","ticker":"FULC","form_type":"8-K","filed_at":"2025-08-28T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Fulcrum Therapeutics provides updated corporate presentation; no specific new facts disclosed in filing.","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company made an updated corporate presentation available on its website for investor meetings.","Filing does not contain any new financial results, clinical data, or material operational changes.","Presentation content not fully included in the submission; details are unknown from this filing alone."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":447775948.460177,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140192,"accession_number":"0000950170-25-099404","cik":1680581,"company_name":"Fulcrum Therapeutics, Inc.","ticker":"FULC","form_type":"8-K","filed_at":"2025-07-29T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Fulcrum Q2 net loss $17.3M; pociredir Phase 1b shows HbF increase 8.6% in SCD","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2025 net loss $17.3M vs net income $55.4M in Q2 2024; cash $214.1M, runway into 2028.","Phase 1b 12 mg cohort: mean HbF increased 8.6% (7.6% to 16.2%); 7/16 patients achieved >20% HbF.","Hemolysis markers improved: indirect bilirubin -37%, LDH -28%, reticulocyte -30%; total hemoglobin +0.9 g/dL.","Safety: pociredir generally well-tolerated, no drug-related SAEs, all treatment-related AEs Grade 1.","20 mg cohort ongoing; data expected by end of 2025; IND for DBA planned Q4 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.56,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":447775948.460177,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157835,"accession_number":"0001193125-25-151276","cik":1680581,"company_name":"Fulcrum Therapeutics, Inc.","ticker":"FULC","form_type":"8-K","filed_at":"2025-06-27T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Fulcrum Therapeutics 2025 annual meeting passes director elections, say-on-pay, auditor ratification","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Class III directors Katina Dorton, Robert Gould, and Kate Haviland elected with 44.6M, 43.8M, and 33.2M votes for, respectively.","Non-binding say-on-pay resolution approved with 46.1M votes for (99.8% of votes cast excluding broker non-votes).","Stockholders selected one year as frequency of future say-on-pay votes (44.9M votes for one year).","Ernst & Young LLP ratified as independent auditor for FY2025 with 49.5M votes for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":447775948.460177,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157834,"accession_number":"0000950170-25-061439","cik":1680581,"company_name":"Fulcrum Therapeutics, Inc.","ticker":"FULC","form_type":"8-K","filed_at":"2025-05-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Fulcrum Q1 net loss $17.7M; pociredir 12mg cohort enrolled, 20mg cohort initiated","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $17.7M for Q1 2025 vs $26.9M in Q1 2024; cash $226.6M at March 31, 2025.","Phase 1b PIONEER trial: enrollment complete for 12mg dose cohort (n=16), 20mg cohort started.","On track to report 12mg cohort data in early Q3 2025 and 20mg cohort data by end of 2025.","R&D expenses fell to $13.4M from $19.8M due to losmapimod discontinuation and Sanofi reimbursement.","Cash runway expected to fund operations into at least 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.28,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":447775948.460177,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176217,"accession_number":"0000950170-25-032355","cik":1680581,"company_name":"Fulcrum Therapeutics, Inc.","ticker":"FULC","form_type":"8-K","filed_at":"2025-03-04T23:59:59+00:00","items":["1.02","9.01"],"status":"ready","headline":"MyoKardia terminates Fulcrum collaboration; Fulcrum loses future milestones and royalties","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["MyoKardia (BMS unit) terminated the collaboration agreement for convenience; effective June 26, 2025.","Fulcrum forfeits all future milestone payments (up to $298.5M per target), royalties, and research cost reimbursement.","Fulcrum had received $10M upfront, $2.5M prepaid research funding, and achieved a $2.5M preclinical milestone.","Parties will continue obligations until June 26, 2025; no further revenues from the agreement after termination."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":447775948.460177,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176216,"accession_number":"0000950170-25-026063","cik":1680581,"company_name":"Fulcrum Therapeutics, Inc.","ticker":"FULC","form_type":"8-K","filed_at":"2025-02-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Fulcrum Therapeutics reports Q4 2024 net loss $16.6M; cash $241M, runway into at least 2027","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full-year 2024 net loss $9.7M vs $97.3M in 2023, driven by $80M Sanofi upfront payment.","Cash and marketable securities $241.0M as of Dec 31, 2024, sufficient into at least 2027.","Phase 1b PIONEER trial of pociredir in SCD: 10 patients enrolled in 12 mg cohort; data expected mid-2025.","Plan to submit IND for Diamond-Blackfan anemia program in Q4 2025.","Phase 3 REACH trial (losmapimod) data to be presented at MDA Conference on March 19, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.16,"consensus_revenue_estimate":null,"consensus_revenue_actual":80000000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":447775948.460177,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176215,"accession_number":"0001193125-25-004942","cik":1680581,"company_name":"Fulcrum Therapeutics, Inc.","ticker":"FULC","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Fulcrum expects ~$240M cash at year-end 2024 (preliminary)","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Expects approximately $240M in cash, equivalents and marketable securities as of Dec 31, 2024 (preliminary, unaudited).","Full Q4 and FY2024 financial results not yet finalized; audit ongoing.","Updated corporate presentation published on January 13, 2025 on company website."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":447775948.460177,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193105,"accession_number":"0001193125-24-284214","cik":1680581,"company_name":"Fulcrum Therapeutics, Inc.","ticker":"FULC","form_type":"8-K","filed_at":"2024-12-23T23:59:59+00:00","items":["1.02","9.01"],"status":"ready","headline":"Sanofi terminates losmapimod deal; Fulcrum loses up to $975M in milestones","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sanofi terminated for convenience the May 2024 collaboration for losmapimod (FSHD) effective April 17, 2025.","Fulcrum received $80M upfront but forfeits all remaining milestones (up to $975M) and tiered royalties.","Fulcrum no longer entitled to global development cost reimbursement; Phase 3 trial obligations continue until termination.","After termination, Fulcrum retains full rights to losmapimod but loses ex-U.S. partner and future payments."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":447775948.460177,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193104,"accession_number":"0000950170-24-125927","cik":1680581,"company_name":"Fulcrum Therapeutics, Inc.","ticker":"FULC","form_type":"8-K","filed_at":"2024-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Fulcrum Therapeutics Q3 net loss $21.7M, cash $257.2M; losmapimod halted, PIONEER trial ongoing","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $21.7M in Q3 2024 vs $24.0M loss in Q3 2023; R&D expenses down to $14.6M from $18.2M.","Cash $257.2M as of Sept 30, 2024, up from $236.2M at Dec 31, 2023, due to $80M Sanofi upfront.","Phase 1b PIONEER trial for pociredir (SCD) advancing; Cohorts 3 (12mg) and 4 (20mg) planned; data expected 2025.","Losmapimod development suspended after Phase 3 REACH failure; company refocuses on pociredir and aplastic anemias.","Cash runway into at least 2027; FY2025 cash burn guided at $55-65M; expects ~$240M cash at end of 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":0.11,"consensus_revenue_estimate":null,"consensus_revenue_actual":80000000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":447775948.460177,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193103,"accession_number":"0001193125-24-256101","cik":1680581,"company_name":"Fulcrum Therapeutics, Inc.","ticker":"FULC","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director James Collins resigns; Rachel King appointed to board of Fulcrum Therapeutics","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["James J. Collins resigned as Class II director effective Nov 12, 2024, not due to any disagreement with the company or board.","Board appointed Rachel King as Class II director to fill the vacancy; term expires at 2027 annual meeting.","King is independent and will serve on Compensation & Human Capital Management Committee.","King receives standard non-employee director compensation including option for 60,000 shares at $3.64 per share."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":447775948.460177,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209484,"accession_number":"0000950170-24-109069","cik":1680581,"company_name":"Fulcrum Therapeutics, Inc.","ticker":"FULC","form_type":"8-K","filed_at":"2024-09-24T23:59:59+00:00","items":["2.05","9.01"],"status":"ready","headline":"Fulcrum Therapeutics reduces workforce from 80 to 51, expects $10M annual savings","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Workforce reduction of 29 employees (36%) to focus on pociredir, DBA, and early discovery; suspends losmapimod.","One-time severance costs of approximately $2 million expected in Q3 2024.","Annual operating expense savings of about $10 million anticipated starting Q1 2025.","Majority of costs incurred by September 30, 2024; implementation substantially complete by Q3 end."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":447775948.460177,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209483,"accession_number":"0001193125-24-217822","cik":1680581,"company_name":"Fulcrum Therapeutics, Inc.","ticker":"FULC","form_type":"8-K","filed_at":"2024-09-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Fulcrum Therapeutics Phase 3 losmapimod trial fails; program suspended","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["REACH trial missed primary endpoint: RSA change p=0.75 vs placebo at week 48.","All secondary endpoints (MFI, shoulder strength, PROs) did not reach statistical significance.","Fulcrum suspends losmapimod development; safety profile consistent with prior studies.","$273.8M cash as of June 30 used for pociredir (SCD), DBA programs, and early discovery."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":447775948.460177,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209482,"accession_number":"0001193125-24-205347","cik":1680581,"company_name":"Fulcrum Therapeutics, Inc.","ticker":"FULC","form_type":"8-K","filed_at":"2024-08-22T23:59:59+00:00","items":["3.02","9.01"],"status":"ready","headline":"Fulcrum Therapeutics exchanges 9.35M shares for pre-funded warrants with RA Capital and another stockholder","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["RA Capital exchanged 8,500,000 shares for a pre-funded warrant for 8,500,000 shares at $0.001 exercise price, no expiration.","Another institutional stockholder exchanged 850,000 shares for pre-funded warrants for 850,000 shares on same terms.","Beneficial ownership blocker set at 9.99%; RA Capital can increase to 19.99% with 61 days' notice.","No cash proceeds to Fulcrum; exchange exempt from registration under Section 3(a)(9) of the Securities Act."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":447775948.460177,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209481,"accession_number":"0000950170-24-088236","cik":1680581,"company_name":"Fulcrum Therapeutics, Inc.","ticker":"FULC","form_type":"8-K","filed_at":"2024-07-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Fulcrum Therapeutics reports Q2 net income of $55.4M, on track for Phase 3 FSHD data by Oct 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net income $55.4M vs net loss $23.8M in Q2 2023; revenue $80M from Sanofi upfront payment.","Cash and securities $273.8M as of June 30, 2024; expected to fund operations into 2027.","Phase 3 REACH trial (losmapimod for FSHD) topline data expected by end of October 2024; 260 patients enrolled.","Collaboration with Sanofi for ex-U.S. losmapimod; $80M upfront received in Q2.","Phase 1b pociredir (SCD) advancing; cohorts at 12 mg and 20 mg once daily planned."],"consensus_eps_estimate":null,"consensus_eps_actual":0.45,"consensus_revenue_estimate":null,"consensus_revenue_actual":80000000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":447775948.460177,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227545,"accession_number":"0001193125-24-162653","cik":1680581,"company_name":"Fulcrum Therapeutics, Inc.","ticker":"FULC","form_type":"8-K","filed_at":"2024-06-17T23:59:59+00:00","items":["5.02","5.07"],"status":"ready","headline":"Fulcrum expands board to 9, elects Colin Hill; stockholders elect directors, ratify auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Board expanded from 8 to 9; Colin Hill elected Class I director, term expiring at 2026 annual meeting.","Hill received automatic grant of 60,000 nonqualified stock options at $7.00/share.","Annual meeting: James Collins, James Geraghty, Alex Sapir elected as Class II directors for 3-year term.","Stockholders ratified Ernst & Young as independent auditor for fiscal year ending December 31, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":447775948.460177,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227544,"accession_number":"0000950170-24-058187","cik":1680581,"company_name":"Fulcrum Therapeutics, Inc.","ticker":"FULC","form_type":"8-K","filed_at":"2024-05-13T23:59:59+00:00","items":["1.01","2.02","9.01"],"status":"ready","headline":"Fulcrum signs $80M upfront Sanofi deal for losmapimod ex-U.S.; Q1 net loss $26.9M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Sanofi pays $80M upfront; Fulcrum eligible for up to $975M in milestones and tiered low-teens to mid-twenties royalties on ex-U.S. sales.","Cash, equivalents, and securities $213.3M at March 31; pro forma ~$293.3M including Sanofi upfront; runway into 2027.","Net loss $26.9M for Q1 2024 vs $24.8M in Q1 2023; R&D expenses $19.8M due to REACH trial advancement.","Phase 3 REACH trial for losmapimod in FSHD on track to report topline data in Q4 2024.","Appointed Patrick Horn, M.D., Ph.D., as CMO; Phase 1b pociredir trial in sickle cell disease expanding to cohorts 3 and 4."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":447775948.460177,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246378,"accession_number":"0000950170-24-020615","cik":1680581,"company_name":"Fulcrum Therapeutics, Inc.","ticker":"FULC","form_type":"8-K","filed_at":"2024-02-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Fulcrum Therapeutics Q4 2023 net loss $24.8M; Phase 3 REACH data expected Q4 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $24.8M in Q4 2023 (vs $26.1M); full-year net loss $97.3M (vs $109.9M).","Cash, equivalents, and marketable securities $236.2M; cash runway into 2026.","Phase 3 REACH trial for losmapimod in FSHD on track for topline data in Q4 2024 after enrolling 260 patients.","Phase 1b PIONEER trial for pociredir in SCD restarted; cohorts evaluating 12 mg and 20 mg daily doses."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.59,"consensus_revenue_estimate":null,"consensus_revenue_actual":2805000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":447775948.460177,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263818,"accession_number":"0000950170-23-059753","cik":1680581,"company_name":"Fulcrum Therapeutics, Inc.","ticker":"FULC","form_type":"8-K","filed_at":"2023-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Fulcrum Therapeutics Q3 2023: net loss $24M, Phase 3 enrollment complete, cash runway extended into 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Completed enrollment in Phase 3 REACH trial of losmapimod for FSHD; topline data expected Q4 2024.","FDA lifted clinical hold for pociredir in sickle cell disease; Phase 1b trial reinitiation underway with amended protocol.","Net loss of $24.0M for Q3 2023 vs $23.7M in prior-year quarter; R&D expenses increased to $18.2M.","Cash, cash equivalents, and marketable securities $257.1M as of Sep 30, 2023; cash runway extended into 2026.","Collaboration revenue $0.8M, down from $1.2M in Q3 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.19,"consensus_revenue_estimate":null,"consensus_revenue_actual":1934000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":447775948.460177,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263817,"accession_number":"0001193125-23-249011","cik":1680581,"company_name":"Fulcrum Therapeutics, Inc.","ticker":"FULC","form_type":"8-K","filed_at":"2023-10-02T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Fulcrum Therapeutics eliminates COO role; Mel Hayes transitions to EVP, Patient Experience","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["COO position eliminated effective Oct 2, 2023; no principal operating officer thereafter.","Mel Hayes remains as Executive Vice President, Patient Experience under amended agreement.","New role has 12-month term; compensation and severance unchanged.","Restructuring aimed at streamlining company functions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":447775948.460177,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":281028,"accession_number":"0001193125-23-217439","cik":1680581,"company_name":"Fulcrum Therapeutics, Inc.","ticker":"FULC","form_type":"8-K","filed_at":"2023-08-22T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Fulcrum Therapeutics announces FDA lifts clinical hold on FTX-6058 IND for sickle cell disease","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA lifted clinical hold on Fulcrum's IND for FTX-6058 on August 22, 2023.","FTX-6058 is a potential treatment for sickle cell disease.","Fulcrum posted a presentation with amended protocol and planned Phase 1b trial details.","Clinical development can now resume; no financial terms disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":447775948.460177,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":281027,"accession_number":"0000950170-23-037574","cik":1680581,"company_name":"Fulcrum Therapeutics, Inc.","ticker":"FULC","form_type":"8-K","filed_at":"2023-08-03T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"Fulcrum Therapeutics reports Q2 net loss $23.8M, closes FSHD trial screening, appoints CFO","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $23.8M in Q2 2023, improved from $34.1M in Q2 2022; cash $278.2M.","Screening closed for Phase 3 REACH trial of losmapimod in FSHD; topline data expected Q4 2024.","Alan A. Musso appointed CFO effective Aug 7, 2023; base salary $450K, 40% target bonus, 432,800 stock option.","Licensed global rights from CAMP4 for Diamond-Blackfan Anemia; clinical hold for FTX-6058 remains unresolved.","R&D expenses fell to $17.8M from $25.0M YoY; cash runway into mid-2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.8,"consensus_revenue_estimate":null,"consensus_revenue_actual":1175000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":447775948.460177,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":281026,"accession_number":"0001193125-23-184748","cik":1680581,"company_name":"Fulcrum Therapeutics, Inc.","ticker":"FULC","form_type":"8-K","filed_at":"2023-07-10T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Fulcrum licenses CAMP4's Diamond Blackfan Anemia program for up to $70M in milestones plus royalties","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Exclusive worldwide license to CAMP4's DBA program, including small molecule compounds and patent rights.","Undisclosed upfront payment; up to $35M in development/regulatory milestones and $35M in sales milestones.","Royalties on net sales: mid-single to low-double digit, subject to reductions for patent loss or generics.","Fulcrum responsible for all development and regulatory costs; CAMP4 may terminate for non-payment or patent challenges.","License expires per product/country upon later of patent expiry, regulatory exclusivity end, or 10 years after first sale."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":447775948.460177,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":299723,"accession_number":"0001193125-23-164435","cik":1680581,"company_name":"Fulcrum Therapeutics, Inc.","ticker":"FULC","form_type":"8-K","filed_at":"2023-06-09T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Fulcrum shareholders reject stock plan amendment, approve officer liability limitation, elect directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders did not approve amendment to 2019 Stock Incentive Plan: 23.7M for, 26.5M against, 48K abstain.","Approved certificate amendment to limit officer liability under Delaware law: 49.0M for, 1.3M against, 16K abstain.","Elected Alan Ezekowitz (41.3M for) and Sonja Banks (42.1M for) as Class I directors for three-year terms.","Ratified Ernst & Young as independent auditor for FY2023: 53.6M for, 8K against, 380K abstain.","Amendment to Restated Certificate filed with Delaware Secretary of State effective June 8, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":447775948.460177,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":299722,"accession_number":"0000950170-23-021958","cik":1680581,"company_name":"Fulcrum Therapeutics, Inc.","ticker":"FULC","form_type":"8-K","filed_at":"2023-05-15T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"Fulcrum Therapeutics appoints Alex Sapir CEO, reports Q1 net loss of $24.8M, FTX-6058 on clinical hold","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Alex Sapir appointed CEO/President effective July 1, 2023; he will serve as special advisor until then.","Esther Rajavelu resigned as CFO effective Apr 21, 2023; Robert Gould appointed interim principal financial officer.","FDA placed FTX-6058 for sickle cell disease on full clinical hold in Feb 2023; active discussions ongoing.","Phase 3 REACH trial of losmapimod in FSHD enrollment on track to complete in second half of 2023.","Q1 2023 net loss $24.8M; cash, equivalents, and marketable securities $297.8M; cash runway into mid-2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":447775948.460177,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":299721,"accession_number":"0001193125-23-091620","cik":1680581,"company_name":"Fulcrum Therapeutics, Inc.","ticker":"FULC","form_type":"8-K","filed_at":"2023-04-05T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Fulcrum Therapeutics CFO Esther Rajavelu resigns effective April 21, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO Esther Rajavelu resigns effective April 21, 2023 to pursue another opportunity.","Company will conduct an executive search for a new chief financial officer.","Rajavelu enters consulting agreement for up to 3 months; receives $52,780/month plus $6,000 initiation fee.","Vested stock option exercise period extended to 12 months after consulting services end."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":447775948.460177,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":319829,"accession_number":"0000950170-23-006834","cik":1680581,"company_name":"Fulcrum Therapeutics, Inc.","ticker":"FULC","form_type":"8-K","filed_at":"2023-03-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"FDA places FTX-6058 on clinical hold; Fulcrum reports Q4/FY2022 results","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA placed full clinical hold on FTX-6058 IND for sickle cell disease; enrollment paused and dosing suspended.","Phase 1b 12 mg cohort showed up to 10% absolute HbF increase; company working to address FDA concerns.","Losmapimod Phase 3 REACH trial enrollment on track to complete in second half of 2023.","Completed $117.3M public offering in January 2023; cash runway extends into mid-2025.","CMO Santiago Arroyo resigned; Iain Fraser appointed Interim CMO, effective March 9, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":447775948.460177,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":319828,"accession_number":"0001193125-23-010273","cik":1680581,"company_name":"Fulcrum Therapeutics, Inc.","ticker":"FULC","form_type":"8-K","filed_at":"2023-01-18T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Fulcrum Therapeutics prices upsized public offering of 9.6M shares at $13.00, expected gross proceeds of $125M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offered 9,615,384 shares at $13.00 per share; gross proceeds of $125 million.","Underwriters granted 30-day option to purchase up to an additional 1,442,307 shares.","Net proceeds estimated at $117.3M ($134.9M if option fully exercised).","Goldman Sachs, SVB Securities, Piper Sandler acting as joint book-running managers.","Offering expected to close on January 20, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":447775948.460177,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":319827,"accession_number":"0001193125-23-009500","cik":1680581,"company_name":"Fulcrum Therapeutics, Inc.","ticker":"FULC","form_type":"8-K","filed_at":"2023-01-17T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Fulcrum announces $100M stock offering and preliminary $202.9M cash position","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary cash, cash equivalents, and marketable securities of ~$202.9M as of Dec 31, 2022.","Commenced underwritten public offering of $100M common stock, with 30-day option for additional $15M.","Terminated ATM equity distribution agreement with Piper Sandler effective Jan 17, 2023.","Goldman Sachs, SVB Securities, Piper Sandler joint book-runners; H.C. Wainwright lead manager."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":447775948.460177,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":319826,"accession_number":"0001193125-23-001193","cik":1680581,"company_name":"Fulcrum Therapeutics, Inc.","ticker":"FULC","form_type":"8-K","filed_at":"2023-01-04T23:59:59+00:00","items":["2.02","8.01","5.02","9.01"],"status":"ready","headline":"CEO transition and positive FTX-6058 Phase 1b data; cash runway into late 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO Bryan Stuart departs; Robert Gould, former CEO/board member, appointed interim CEO effective Jan 3, 2023.","FTX-6058 granted FDA Fast Track for SCD; Phase 1b shows HbF increases up to 9.5% at 6 mg, generally well tolerated.","Plan to complete enrollment in Phase 3 REACH trial of losmapimod in FSHD during 2H 2023.","Cash runway expected to fund operations into late 2024; next FTX-6058 data update expected in Q4 2023.","Phase 1b enrollment ongoing in 12 mg cohort; dose-dependent HbF increase observed across adherent patients."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":447775948.460177,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":338040,"accession_number":"0000950170-22-022910","cik":1680581,"company_name":"Fulcrum Therapeutics, Inc.","ticker":"FULC","form_type":"8-K","filed_at":"2022-11-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Fulcrum Therapeutics Q3 net loss $23.7M; cash $221.8M; selected 12mg dose for FTX-6058 SCD trial","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $23.7M vs $20.7M year ago; collaboration revenue fell to $1.2M from $4.9M due to Acceleron wind-down.","Cash, equivalents, and marketable securities $221.8M; cash runway guidance extended into late 2024.","Completed equity raise of ~$80.8M net proceeds in August 2022.","Selected 12mg as dose for next FTX-6058 Phase 1b cohort in sickle cell disease; enrollment continues.","Appointed Santiago Arroyo as CMO and Jeff Jacobs as CSO; losmapimod Phase 3 REACH trial enrollment ongoing."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.97,"consensus_revenue_estimate":null,"consensus_revenue_actual":5657000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":447775948.460177,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":338039,"accession_number":"0001193125-22-265260","cik":1680581,"company_name":"Fulcrum Therapeutics, Inc.","ticker":"FULC","form_type":"8-K","filed_at":"2022-10-19T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"President of R&D Judith Dunn resigns; position eliminated; CEO assumes direct oversight","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Judith Dunn resigns as president, R&D; separation agreement signed October 14, 2022.","Dunn remains employed through Jan 3, 2023, then provides biotech consulting in transitional capacity.","Clinical development organization now reports directly to CEO Bryan Stuart; president R&D role eliminated.","Company continues search for Chief Medical Officer as previously announced.","Extended 6-month exercise period for stock options post-separation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":447775948.460177,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":355396,"accession_number":"0001193125-22-227590","cik":1680581,"company_name":"Fulcrum Therapeutics, Inc.","ticker":"FULC","form_type":"8-K","filed_at":"2022-08-23T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Fulcrum Therapeutics completes $80.9M underwritten public offering","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Underwriters exercised option to buy 1,438,618 additional shares at $7.82/share.","Additional net proceeds of ~$10.6M; total net proceeds ~$80.9M after discounts and expenses.","Overallotment option closed on August 23, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":447775948.460177,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":355395,"accession_number":"0001193125-22-222443","cik":1680581,"company_name":"Fulcrum Therapeutics, Inc.","ticker":"FULC","form_type":"8-K","filed_at":"2022-08-17T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Fulcrum Therapeutics announces $75M public offering of common stock at $7.82/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["9,590,792 shares offered at $7.82/share; gross proceeds $75 million.","Net proceeds estimated at $70.3 million ($80.9 million if underwriters exercise full 30-day option for 1,438,618 additional shares).","Goldman Sachs & Co. and SVB Securities act as lead joint book-running managers; closing expected on August 18, 2022.","Company subject to 60-day lock-up; directors and executive officers subject to 30-day lock-up."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":447775948.460177,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":355394,"accession_number":"0001193125-22-217954","cik":1680581,"company_name":"Fulcrum Therapeutics, Inc.","ticker":"FULC","form_type":"8-K","filed_at":"2022-08-11T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Fulcrum Therapeutics promotes Mel Hayes to COO with salary increase and stock option grant","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Mel Hayes promoted from chief commercial officer to chief operating officer effective August 9, 2022.","Annual base salary increased to $453,000 retroactive to July 1, 2022.","Granted option to purchase 137,000 shares at $7.40 per share, vesting over four years.","Hayes previously served as CCO since September 2021; prior roles include Sanofi-Genzyme and Bioverativ.","Employment agreement setting terms for severance and change-in-control benefits filed as Exhibit 10.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":447775948.460177,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":355393,"accession_number":"0000950170-22-016633","cik":1680581,"company_name":"Fulcrum Therapeutics, Inc.","ticker":"FULC","form_type":"8-K","filed_at":"2022-08-11T23:59:59+00:00","items":["2.02","2.05","9.01"],"status":"ready","headline":"Fulcrum Therapeutics Q2 net loss $34.1M; cuts 18 jobs, saves $40-50M, cash into mid-2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Net loss $34.1M ($0.65 per share) vs $19.6M in Q2 2021; cash $169M as of June 30.","Workforce reduction of 18 positions (~25% of planned headcount) primarily in discovery, research, and G&A.","Expects ~$40-50M operating expense savings fully realized by mid-2024; cash runway extended into mid-2024.","Phase 1b data for FTX-6058 in SCD showed HbF increases up to 6.3%; first patient enrolled in Phase 3 REACH trial for losmapimod in FSHD.","Promoted Mel Hayes to COO and Curt Oltmans to Chief Legal Officer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":447775948.460177,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":355392,"accession_number":"0001193125-22-191340","cik":1680581,"company_name":"Fulcrum Therapeutics, Inc.","ticker":"FULC","form_type":"8-K","filed_at":"2022-07-11T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Chief Medical Officer Chris Morabito resigns effective July 13, 2022","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Chris Morabito, M.D., stepped down as Chief Medical Officer of Fulcrum Therapeutics.","Resignation effective July 13, 2022; he left to pursue another opportunity.","No replacement announced; departure not due to any disagreement with company.","Morabito's resignation follows no known operational or financial disputes.","Fulcrum did not provide details on interim CMO or search timeline."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":447775948.460177,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":373550,"accession_number":"0001193125-22-171957","cik":1680581,"company_name":"Fulcrum Therapeutics, Inc.","ticker":"FULC","form_type":"8-K","filed_at":"2022-06-10T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Fulcrum reports positive Phase 1b data for FTX-6058 in sickle cell disease; HbF up 6.3%","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["FTX-6058 achieved up to 6.3% increase in fetal hemoglobin (HbF) over baseline in Phase 1b trial.","Three evaluable subjects all showed HbF increases by day 28; maximal levels may not yet be reached.","FTX-6058 was generally well-tolerated; no serious TEAEs or discontinuations due to TEAEs.","Company plans to complete enrollment in current and two additional dose cohorts by end of 2022, with registrational trial start in 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":447775948.460177,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":373549,"accession_number":"0001193125-22-171026","cik":1680581,"company_name":"Fulcrum Therapeutics, Inc.","ticker":"FULC","form_type":"8-K","filed_at":"2022-06-09T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Fulcrum Therapeutics reports 2022 annual meeting vote results","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected Kate Haviland, Katina Dorton, Robert Gould as Class III directors for three-year term ending 2025.","Director vote results: Haviland 25,135,506 for / 5,600,007 withheld; Dorton 27,146,569 for / 3,588,944 withheld; Gould 26,665,833 for / 4,069,680 withheld.","Ratified Ernst & Young LLP as independent auditor for FY2022: 34,538,061 for, 20,325 against, 10,946 abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":447775948.460177,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-06-09T23:59:59+00:00|373549"}